ARKUDA Therapeutics

Leveraging new insights into progranulin and lysosomal biology to discover therapies to change the trajectory of neurodegenerative disease.

[ARKUDA Therapeutics @ArkudaTx]

This week at #AAIC2023, Arkuda Therapeutics presented preclinical data on lead development candidate ARKD-104 for the treatment of GRN-related frontotemporal dementia. Read more: https://t.co/7zI6n3ckOA

[ARKUDA Therapeutics @ArkudaTx]

Congratulations to @KukarLab on this important work (w/ contributions from Arkuda team members Chris Holler, Bonne Thompson, and Giuseppe Astarita, and @eraserh34d). It's the granulins! Team @arkudatx continues to work tirelessly to move our programs closer to the clinic.

[ARKUDA Therapeutics @ArkudaTx]

Congratulations to Raymond Hurst and the rest of the Arkuda Therapeutics team for a great presentation at #adpd2023, "Therapeutic Potential of ARKD-104 for Treatment of Frontotemporal Dementia and Other Neurodegenerative Diseases"

#endFTD #neurodegeneration

[ARKUDA Therapeutics @ArkudaTx]

Happy #IWD2023!
Today and every day we celebrate the incredible achievements of women in different aspects of life all over the world.
#EmbraceEquity

[ARKUDA Therapeutics @ArkudaTx]

In honor of #InternationWomensDay, we want to reaffirm our commitment every day to creating a more diverse, inclusive and equitable workplace. All of us have an important role to play in making sure that we #BreakTheBias.

#iwd2022 #wherepeoplematter

[ARKUDA Therapeutics @ArkudaTx]

We are delighted to announce that Arkuda has closed a $64M Series B co-led by Cormorant and Pivotal bioVenture Partners to advance novel therapeutics targeting lysosomal biology to change the trajectory of neurodegenerative diseases. Read more: https://t.co/CFA9fxNHxi

[ARKUDA Therapeutics @ArkudaTx]

At this week’s virtual AD/PD 2021, we're sharing new preclinical data (P501/#606) on the potential of our compounds for the treatment of Parkinson’s disease with GBA1 mutations (PD-GBA). Learn more here: https://t.co/0FZjoC6ZAE

#ADPD2021 #Parkinsons #Alzheimers #Neuroscience

[ARKUDA Therapeutics @ArkudaTx]

Team Arkuda celebrates strong women everywhere on this #InternationalWomensDay ! Proud to raise our hands together as we #ChooseToChallenge and encourage everyone to commit to shaping a more inclusive world. #IWD2021 #WomenInScience

[ARKUDA Therapeutics @ArkudaTx]

Congratulations to Team #NSP and @BluefieldProj! We are thrilled to be involved with this collaborative effort which will provide important insights to drive our shared mission to #endFTD

[Bluefield Project @BluefieldProj]

Enrollment for the Neurofilament Surveillance Project (#NSP), sponsored by @BluefieldProj, is now open! Individuals participating in @allftd who are members of families with inherited #FTLD are eligible to participate in this important study. Learn more at https://t.co/HvXpk2rKbR

[ARKUDA Therapeutics @ArkudaTx]

We're thrilled to announce the appointment of Pascale Witz to our BoD. Pascale is an accomplished leader and #biotech advisor, and we look forward to working with her as we advance our pipeline to treat FTD-GRN and other neurodegenerative diseases. https://t.co/AaWeacxiZK #endFTD

[ARKUDA Therapeutics @ArkudaTx]

Don’t miss tomorrow’s @labcentral webinar on Innovation & Biotech in the Time of COVID-19. Arkuda CEO @GerhardKoenig1 will join @ca_webb and @JFruehauf to discuss learnings and insights from MA’s Phase 1 reopening, as well as planning for the future. https://t.co/4sbysJlcVK

[LabCentral @LabCentral]

We're back with Innovation & Biotech in the Time of COVID-19 on Tuesday, June 2. Join moderator @JFruehauf to hear from Cambridge biotech leaders @GerhardKoenig1 and @ca_webb discussing the lessons we've learned from re-opening Phase 1. https://t.co/NDUBOSEGzV

[Gerhard Koenig @GerhardKoenig1]

Impressive study (>2000 individuals) published in @TheLancetNeuro by Quiroz et al. #biomarker NfL increases in early onset familial #Alzheimer's disease cases 22yrs before (!) onset of MCI, significance ~3yrs before. Important signal for drug development in #neurodegeneration

[Bruce Booth @LifeSciVC]

"Reflections of an Immigrant CEO"

@ArkudaTx CEO Gerhard Koenig opens up in his debut From The Trenches post on the cultural learnings of leading a US-based biotech as a immigrant.

https://t.co/Xh89XcSdLj

[ARKUDA Therapeutics @ArkudaTx]

We are proud to help support the @LS_Cares #COVID19 Fund and get resources where they are needed most right now. #LSCImpact #FrontLineHeroes #StayHomeSaveLives

Will you join us? https://t.co/LfmmNIrnwx.

[ARKUDA Therapeutics @ArkudaTx]

Ray also has an extensive #biopharma background, having worked in companies of all sizes. He will be leading studies to understand relationships between experimental compounds and their desired effects to help guide clinical development. https://t.co/9EdVrx3rrK

[ARKUDA Therapeutics @ArkudaTx]

We're excited to welcome two #biotech industry veterans to the Arkuda management team. Serena Hung joins as Head of Clinical Development, and Ray Hurst as Vice President of Pharmacology, to advance our compounds to treat FTD-GRN to the clinic. #endFTD https://t.co/1HNPGyaQ8i

[ARKUDA Therapeutics @ArkudaTx]

Serena is a board-certified neurologist w/ clinical research experience spanning industry and academia. At Arkuda she will be applying the latest knowledge, insights and methodologies to create plans to demonstrate and understand compound efficacy/safety. https://t.co/mpGpZ631bh

[AD/PD - Advances in Science & Therapy @adpdnet]

Don’t forget that all the content from #AATADPD 2020 is available on the platform until 30 June 2020, including Forum Discussions, webcast sessions, e-posters and more.
All registered participants can still browse the sessions!
👉 Log in now: https://t.co/tE1i1Bfz6e

[ARKUDA Therapeutics @ArkudaTx]

#ICYMI Last week we shared a positive update on our compounds for the treatment of GRN-Related Frontotemporal Dementia at the @adpdnet virtual meeting. Check out our poster for more about PGRN biology and our small molecules: https://t.co/eTqqARIP9h #FTD #Dementia #AATADPD